17 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorderRecruitingPhase 22026-10-06NCT06902558
Urinary Chloride and Sodium Changes and Residual Congestion in Acute Heart Failurecardiovascular disorder, heart disorder, heart failureRecruitingNot stated2026-09-28NCT07597512
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fractioncardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-09-24NCT06736574
Computerized Registry of Patients With Venous Thromboembolism (RIETE)Embolism and Thrombosis, Thromboembolism, cardiovascular disorder, vascular disorder, venous thromboembolismRecruitingNot stated2026-09-21NCT02832245
Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal CandidiasisCandidal PeritonitisActive, not recruitingPhase 42026-09-16NCT06985758
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast CarcinomaRecruitingPhase 22026-07-30NCT06486883
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T TherapyChemically-Induced Disorders, Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, neoplasm, nervous system disorder, poisoning, toxic encephalopathyRecruitingNot applicable2026-07-28NCT07173166
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver diseaseActive, not recruitingPhase 32026-07-02NCT04849728
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiationFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorderActive, not recruitingPhase 22026-06-17NCT03833479
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinoma, squamous cell neoplasmActive, not recruitingPhase 1 / Phase 22026-06-04NCT05784012
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesNeoplasms by Site, Skin and Connective Tissue Diseases, brain disorder, breast cancer, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder, skin disorderActive, not recruitingPhase 22026-05-08NCT06048718
NADIM II: Neo-Adjuvant ImmunotherapyNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-04-30NCT03838159
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genitourinary Cancer, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, transitional cell carcinoma, urinary system disorderRecruitingNot stated2026-02-17NCT06724159
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaB-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 22025-11-28NCT07254754
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsAmyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, proteostasis deficienciesActive, not recruitingPhase 32025-10-14NCT04988386
Study of PYX-106 in Solid TumorsSolid TumorActive, not recruitingPhase 12025-08-03NCT05718557
Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue SarcomasAdvanced Soft-tissue SarcomaActive, not recruitingPhase 1 / Phase 22025-03-21NCT05809830